Cytokinetics, Incorporated (CYTK)

69.00 +1.00 (+1.47%) At close: 04:00PM EDT

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 423

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Robert I. Blum	CEO, President, Principal Financial Officer & Director	1.33M	9.61M	1964
Mr. Robert C. Wong	VP & Chief Accounting Officer	495.72k	N/A	1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	839.66k	586.17k	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	752.84k	N/A	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	21.94k	N/A	1942
Mr. Jeff Lotz	Vice President of Sales & Operations	N/A	N/A	N/A
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	N/A	N/A	N/A
Mr. Steven M. Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	N/A	N/A	1959
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer	N/A	N/A	N/A
Mr. John O. Faurescu Esq.	VP, Associate General Counsel & Corporate Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Corporate governance

Cytokinetics, Incorporated’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.